June 2, 2007 

 

The new version will be implemented in the second half of the year, and sales of some of the prescription drugs will be severely reduced. 

 

The new edition of the health care system, which is expected to be implemented in the second half of the year, was announced at the beginning of the year. Part of the implementation of the new medical insurance directory will determine the prescription drug companies: life and death in the new health care product catalog, there are living room, pharmaceutical enterprises can boost its soft power, provide good academic support and service support in serious; But if the product is not the drug companies in the new medical insurance directory, sales will be more serious, the enterprise or transfer sales positions to the outside of the fierce competition of channel sales and OTC sales channels, the third terminal channel sales, or enterprise facing elimination or be acquired. 

 

This year's national health insurance directory with the previous version of the national health insurance directory there is a big difference: some of the pharmaceutical enterprise "big variety" the limits of the scope of expanded, in the status of medical institutions, there are many restrictions on diseases and the use of the crowd; And even if the product gets into the health care directory, there is no health care payment policy in some provinces. These restrictions will affect the development of some of the mainstream prescription drugs companies, and sales of some companies will be more severe. 

 

In the beginning, the small and medium enterprises with high quality resources will be able to overtake them. 

 

As we all know, product advantage is the root of competition for pharmaceutical companies. A good main product often determines the fate of a pharmaceutical company. Many of these companies have been struck by one or two blockbuster products. As the province's health care inventory increases, there may be a spring in the form of small and medium-sized pharmaceutical companies with star products or gold items, especially those with high quality Chinese medicine. 

 

Some small and medium-sized pharmaceutical companies, because of their products' advantages and uniqueness, will stand out in the fierce competition and become the gold products of the health care catalogue. These included medical insurance directory of small and medium-sized pharmaceutical companies have a lot of development opportunities, in the market competing goods of many coppi, this is the advantage of varieties of charm. These small and medium drug companies will be singing along in "spring" and are expected to overtake on the "velodrome". 

 

Chinese medicine and beverage companies have suffered a bloody storm, and companies under 100 million yuan are out of business. 

 

Chinese medicine yinpian enterprise, especially some smaller Chinese medicine yinpian enterprise, due to the Chinese medicine yinpian quality problems appeared frequently, a fly inspection areas, lead to in the first half of the year has been troubled, some enterprises have been eliminated. In the first half of the year, Chinese medicine companies accounted for nearly half of the 40 companies that had received GMP certificates. Having strong financial strength and the ability to resist risk is an urgent problem for Chinese medicine companies. 

 

As the country and the relevant department of Chinese medicine yinpian regulation, the relevant policy and system, Chinese medicine yinpian will increasing the difficulty of the production and operation enterprises. The ability to improve quality and competitiveness through improved manufacturing processes and equipment will be able to overcome difficulties for companies with a large scale of more than 100 million. But for small and medium-size Chinese medicine companies, which are under 100 million yuan, the lack of financial strength and competitiveness is a pain in the heart. 

 

According to the national bureau of statistics show that 2016 sales income 192.2 billion yuan, Chinese medicine yinpian industry accounts for more than the minimum, in the pharmaceutical industry is only 6.5%, but maintain high growth of 13.5%, higher than the overall economic growth in western medicine, rendering good momentum of development. In 2017, the market for traditional Chinese medicine will be nearly 400bn because of national policy. 

 

Chinese medicine yinpian, as one of the important pillar industry of Chinese medicine, to further standardize the production process and quality control standard, believe in the near future, Chinese medicine yinpian market will outshine others, enjoy a rapid growth. 

 

Drug stores and clinics are becoming increasingly sophisticated and popular with consumers. 

 

As the country's health reform deepens, prescription drug companies are moving into pharmacies, where prescription drugs are increasingly sold. With the profound impact of the entire medical environment, retail outlets with pharmacies and clinics are becoming more and more popular with consumers. 

 

Hierarchical diagnosis and rapid fall to the ground, grade hospital medical technology costs rise ceaselessly, make part of the original hospital patients sick to the hospital's habits are changing, to the community to the nearest clinic or possess the qualifications of the clinic pharmacy doctor is accepted by more and more people. In clinic, medicine diagnosis with clinic, medicine diagnosis shop after shop to see the doctor professional doctor's prescription to the pharmacy to get medicine, can get a quick, effective treatment, see a doctor to the hospital and saved the registration fee and time line. 

 

Rapid along with our country entering an aging society, "a serious illness to the hospital, ailment to the community or pharmacy" concept has been deeply rooted in the hearts of the people, as the pharmacy + clinic model matures, clinic doctors own quality enhancement and improvement of the equipment, pharmacy + clinic model is widespread promotion, believe this model will have a larger cause in our country, the Chinese version of "Mayo clinic" is expected to appear. 

 

5. There are resources force pharmaceutical enterprises develop new sales model, prescription drugs, OTC, the third terminal, KA, courtyard outside, big health division "six carriages" neck and neck situation will start to appear. 

 

Previous sales models have been relatively flat, either over-the-counter, OTC or third terminal sales. But with the growing complexity of the medical environment, it is difficult to "play around" China's pharmaceutical market with just a few sales models. 

 

Part have resources and forward-looking of medical enterprises entrepreneurs with the advantages of itself never try before expanding the sales model, here we call it "the new sales model". The "new sales model" includes the third terminal, KA, out-of-court sales, and health, and has a successful model in every sales model. Have resources of pharmaceutical enterprises need to seriously study, combine its own advantage complement each other, will be in the current severe medical market instead, new as something different. One well-known domestic pharmaceutical companies, for example, in the field of the original control pin to do the country's first 3 armour, the company boss vision, in the country to vigorously advocate big health industry background, the first to set up the health department. A few short years, its big sales and scale of the health department has been far beyond the original third terminal control the size of the pin mode, become another core enterprise's profit growth point. 

 

Drugstore chains are popping up, and large and medium-sized drugstores are competing to bring in a new round of pharmacy chains. 

 

The already listed chain stores, such as the common people, yifeng and single-minded, are still accelerating outside the province. In the latest changes, they have slowed to a point where they have gradually shifted to building their own stores. The reason for this is that acquisitions are relatively fast compared to building their own stores, but there is also a lot of uncertainty about the quality of the acquisition and the post-acquisition uncertainty. There will be less uncertainty over the quality of self-built stores and the uncertainty over the acquisition. 

 

Guangdong's regional leading forest chain, shandong's regional leader gargle jade civilians have entered the countdown to the listing. Some other famous pharmaceutical chain, such as the friend Kang Liansuo, YanXiTang chain is also making planning on the market and accelerate the speed of opening and mergers and acquisitions, in order to in the near future can be listed on the main board. The new store is aiming for 1,000 new stores this year, with an average of three a day expanding at a rapid pace. The goal is to move towards capital markets in 3-5 years, with new leaps and bounds. 

 

The big and medium-sized pharma companies are no longer the big pharma companies, but small and medium-sized pharmaceutical companies with branded health care and brand OTC products. 

 

The merger of large and medium-sized pharmaceutical companies is still accelerating, but the eyes are becoming more and more critical. In the case of the big and large, the pharmaceutical companies that are bought and bought are often glossy, the bad assets are higher, and the merger will be a problem. And have a brand of health care, and OTC brand of small and medium enterprises because of its brand awareness and product awareness, when to be acquired by the advantages of large and medium-sized enterprises in favor. The brand and popularity of the product are not made for a while, but they have to go through a long journey. Products after long-term use has been in the consumer mind formed the brand, brand is competitive, with the comprehensive competitiveness have demonstrated the strong profitability, in this case, the large and medium-sized enterprises to the eye on very vision and forward-looking. 

 

I have the honor to participate in the people trusted group purchase Jiang Xijiu China pharmaceutical co., LTD., the whole process from the acquisition research, negotiation, signing, market transition basically accord with the above path. There are no big names in the company, and the base sales are small. But the main product jiuhua hemorrhoid bolt has certain brand influence, can excavate the market space bigger, have the big attraction to the m&a party. 

 

The changing policies of the industry have led to a bewilderment of the strategic objectives of large pharmaceutical companies, and large pharmaceutical executives are leaving the company. 

 

Uncertainty in the industry has led to uncertainty and led to the departure of some large pharmaceutical executives. This is an era of heroic assessment. Corporate executives is the soul of the drug companies, their arrival or departure, short-term strategy to drug companies or the formation of long-term strategy will have a big impact, sometimes can be fatal. New executives will bring in new strategies and new cultures, adding too much uncertainty. In today's industry, it is a bad day for businesses. 

 

Relatively stable senior team is a lot of confusion in the pharmaceutical enterprises need to adhere to a basic principle, because executives is very important for the development of a company, he was familiar with the harm and leave the enterprise especially big. Only at the top level can the strategy be stable, and the development of the enterprise can be sustainable, and the enterprise can commit to long-term development. Throughout history, all be built to last in the world top 500 enterprises, its core executives are have very personality charm and long service in the company and development together with the company. 

 

The primary medical department of the pharmaceutical industry has shifted its focus to sales management and services. 

 

The country is energetically advocating the basic medical treatment, the big disease, the difficult and the disease to the hospital, the small disease to the primary medical establishment, the drugstore. We have made significant investment in the development of community-level medical care and new agriculture. As a specially designed for basic medical service of the pharmaceutical companies, their focus is no longer just selling products, but will shift the focus to sales management and service. 

 

In the past, these pharmaceutical companies had a real stake in the basic medical market by carefully studying consumers and products. But as the reform of the national health system progresses, the needs of the primary medical institutions have also changed. First they need to learn new knowledge to meet the growing demand of consumers; Second, the state has a large area to stop the infusion, and the basic medical institutions need new and alternative skills and methods to realize medical ethics and profit. Finally, they have new requirements for the comprehensive ability of medical enterprise personnel quality and sales management service. 

 

Directed against these new requirements, grassroots medical institutions as drug firms grassroots health group, must comply to, to fully understand and meet the needs of grassroots medical institutions, should constantly improve their level of skills and at the same time, better professional services for grassroots medical institutions. 

 

Third terminal green therapy is getting more and more hot, and brands are starting to stand out. 

 

Third terminal clinics and pharmacies play a vital role in the process of community-level health reform. At the same time, the third terminal clinics and pharmacies have found a green treatment that can replace the infusion completely, while the state has banned the infusion of fluids on a large scale. 

 

Chinese traditional Chinese medicine green therapy has acupuncture, paste, cupping, moxibustion, massage etc., the green treatment economy is applicable, safe and effective. By using these green therapy, maximum limit reduce drugs and infusion method, the harm of human body and help patients with primary care and cure the disease, also maintain the third terminal clinic, pharmacy source of profits. 

 

Many green therapy brands stand out, such as a well-known drug firms, henan in 2016 by doctors at the grass-roots level training + professional academic promotion methods, himself a products eliminated will miraculously did a $. The state advocates, the people need, the third terminal green therapy will be used more and more by the well-known drug companies, the brand enterprise starts to stand out.